Clinical and bacteriologic efficacy of amoxycillin b.d. (45 mg/kg/day) versus amoxycillin t.d.s (40 mg/kg/day) in children with group A beta-hemolytic streptococcal tonsillopharyngitis

This randomized, observer-blind, multicenter, parallel-group study compared the clinical and bacteriologic efficacy and safety of amoxycillin, 45 mg/k g/day b.d. and amoxycillin, 40 mg/kg/day t.d.s. after 7 days of treatment i n 517 children with acute bacterial tonsillopharyngitis. At the end of trea tment, a successful clinical response was recorded in more than 96% of pati ents in each of the treatment groups, A similar result was obtained at foll ow-up. Among those patients who were bacteriologically evaluable at the end of treatment, a successful bacteriologic response was achieved in more tha n 94% in each treatment group. Both treatments were well tolerated. Drug-re lated adverse events were recorded in just 12 patients (4.6%) in the b.d, g roup and six (2.4%) in the t.d,s. group. The study demonstrated that a twic e-daily regimen of amoxycillin, 45 mg/kg/day, was as effective and as well tolerated as the standard three-times-daily regimen of amoxycillin, 40 mg/k g/day, in the treatment of acute bacterial tonsillopharyngitis in children.